retatrutide triple agonist gip glp-1 glucagon phase 3 2025 Dr Who Makes Retatrutide? Company Behind

Without physiological support, many individuals regain weight once the program ends

The market is expanding because GLP-1 prescriptions moved beyond a narrow diabetes base and became more common in weight management by late 2025, which widened the pool of users who need help with protein intake, muscle retention, and micronutrient balance

Even telehealth follow-ups may carry fees unless they are bundled into your treatment plan

Medical Disclaimer This article is for educational and informational purposes only

Journal of Basic and Clinical Physiology and Pharmacology

Many women report increased cravings, particularly for carbohydrate-rich foods, and difficulty feeling satisfied after meals